Fish Oil Emulsion Reduces Liver Injury and Liver Transplantation in Children with Intestinal Failure-Associated Liver Disease: A Multicenter Integrated Study.
Fish Oil Emulsion Reduces Liver Injury and Liver Transplantation in Children with Intestinal Failure-Associated Liver Disease: A Multicenter Integrated Study.
复制标题
鱼油乳剂减少肠衰竭相关肝病儿童的肝损伤和肝移植：一项多中心综合研究。
DOI：
10.1016/j.jpeds.2020.09.068
复制
发表时间：
2021-03
期刊：
影响因子：
--
通讯作者：
Puder M
中科院分区：
文献类型：
--
作者：
Gura KM;Premkumar MH;Calkins KL;Puder M
比较接受鱼油脂肪乳剂（FOLE）或大豆油脂肪乳剂（SOLE）治疗的肠衰竭相关肝病（IFALD）儿童的转氨酶与血小板比率指数（APRI）、肝移植和死亡率。在这项多中心综合分析中，将FOLE接受者（1 g/kg/d）（n=189）与SOLE给药的历史对照（高达3 g/kg/d）（n=73）进行了比较。与SOLE相比，FOLE接受者在基线时的直接胆红素水平更高（5.8 vs. 3.0 mg/dL，P < .0001）。在FOLE接受者中，65%的胆汁淤积消退，而SOLE接受者为16%（P<0.0001）。当基线评分分别与胆汁淤积消退和研究结束相比较时，FOLE组APRI评分改善（1.235 vs. 0.810和0.758，P<0.02），但SOLE组恶化（0.540 vs. 2.564和2.098，P≤0.0003）。FOLE组的肝移植率低于SOLE组（4% vs. 12%，P=0.0245）。与基线DB相比，FOLE受试者的肝移植概率低于SOLE受试者（DB为2 mg/dL时为1% vs 9%; DB为12.87 mg/dL时为8% vs 35%，P=0.0022）。死亡率相似（FOLE vs. SOLE：DB为2 mg/dL时为10% vs. 14%; DB为12.87 mg/dL时为17% vs. 23%，两者P=0.36）。与SOLE相比，FOLE受体胆汁淤积消退率较高，APRI较低，肝移植较少。这表明，当DB达到2 mg/dL时，FOLE可能是IFALD儿童的首选胃肠外脂肪乳剂。Clinicaltrials.gov：NCT 00910104和NCT 00738101
To compare aminotransferase with platelet ratio index (APRI), liver transplantation, and mortality rates between children with intestinal failure-associated liver disease (IFALD) who received fish oil lipid emulsion (FOLE) or soybean oil lipid emulsion (SOLE). In this multicenter integrated analysis, FOLE recipients (1 g/kg/d) (n=189) were compared with historical controls administered SOLE (up to 3 g/kg/d) (n=73). Compared with SOLE, FOLE recipients had a higher direct bilirubin level at baseline (5.8 vs. 3.0 mg/dL, P < .0001). Among FOLE recipients, 65% experienced cholestasis resolution vs. 16% of SOLE (P<0.0001). APRI scores improved in FOLE (1.235 vs. 0.810 and 0.758, P<0.02) but worsened in SOLE recipients (0.540 vs. 2.564 and 2.098, P≤0.0003) when baseline scores were compared with cholestasis resolution and end of study, respectively. Liver transplantation was reduced in FOLE vs. SOLE (4% vs. 12%, P=0.0245). The probability of liver transplantation in relation to baseline DB was lower in FOLE vs SOLE recipients (1% vs. 9% at DB of 2 mg/dL; 8% vs 35% at DB of 12.87 mg/dL, P=0.0022 for both). Death rates were similar (FOLE vs. SOLE: 10% vs. 14% at DB of 2 mg/dL; 17% vs. 23% at a DB of 12.87 mg/dL, P=0.36 for both). FOLE recipients experienced a higher rate of cholestasis resolution, lower APRI, and fewer liver transplants compared with SOLE. This demonstrates that FOLE may be the preferred parenteral lipid emulsion in children with IFALD when DB reaches 2 mg/dL. Clinicaltrials.gov: NCT00910104 and NCT00738101
登录
查看更多内容
DOI：
10.1097/mpg.0000000000000632
发表时间：
2015-03-01
影响因子：
2.9
作者：
Dezsofi, Antal;Baumann, Ulrich;Knisely, Alexander S.
通讯作者：
Knisely, Alexander S.
影响因子：
3.4
作者：
Calkins, Kara L.;Dunn, James C. Y.;Venick, Robert S.
通讯作者：
Venick, Robert S.
影响因子：
5.1
作者：
Gura, Kathleen;Premkumar, Muralidhar H.;Puder, Mark
通讯作者：
Puder, Mark
影响因子：
3.4
作者：
Rumbo, Carolina;Ines Martinez, Maria;Gondolesi, Gabriel
通讯作者：
Gondolesi, Gabriel
影响因子：
13.5
作者：
Mutanen, Annika;Lohi, Jouko;Pakarinen, Mikko P.
通讯作者：
Pakarinen, Mikko P.